Value-based pricing for oncology products in Germany requires a different approach to pre-launch price forecasting. GPI conducted primary research with German payers to identify how value is assessed across 23 attributes grouped into four domains. The results show clinical benefit accounts for 52% of payer value perception, trial design 37%, and burden 11%, reflecting precisely how the G-BA benefit assessment process works under AMNOG in practice.
The research covers both the comparator selection approach and the analogue benchmarking approach for indications where no direct comparators exist, demonstrated through two real-world case studies including one achieving 0.92% accuracy against an actual post-AMNOG reimbursement price. Download below.
